Pular para o conteúdo

Zepbound Returns to CVS Caremark as Massachusetts Faces Equity Pushback on GLP-1 Cuts — October 01, 2026

1 de outubro de 2026 · 10 min

Notas do episódio

Zepbound is back on CVS Caremark's standard commercial formulary starting October 1, but employers still decide, while Massachusetts critics press the state to undo its GLP-1 weight-loss coverage cuts. Plus a JAMA Health Forum Medicaid study on prior authorization, Lilly-sponsored ACHIEVE-4 heart-safety data for Foundayo in The Lancet, and California's new CalRx GLP-1 law.

In this episode
  1. CVS Caremark Adds Zepbound Back October 1, 2026: What to Ask HR Before Open Enrollment — Skinnyvip

    CVS Caremark Adds Zepbound Back October 1, 2026: What to Ask HR Before Open Enrollment # CVS Caremark Adds Zepbound Back October 1, 2026: What to Ask HR Before Open Enrollment Dr. SkinnyVIP September 15, 2026 ~9 min read Formulary details current as of September 15, 2026 This guide summarizes CVS Caremark’s May 28, 2026 announcement and standard commercial formulary template as of the…

  2. Critics say GLP-1 coverage shift raises equity issues — The Boston Globe

    # Critics say GLP-1 coverage shift raises equity issues Author: Alison Kuznitz Published: 2026-09-30T21:56:03.616000+00:00 Source: bostonglobe.com (bostonglobe.com) Language: en ## Story Critics say GLP-1 coverage shift raises equity issues # Critics say GLP-1 coverage shift raises equity issues A woman holds a Wegovy injector pen in her Wenatchee, Wash., home, on June 3, 2024. M. SCOTT…

  3. Medicaid Coverage of Obesity GLP-1s May Shift From Diabetes Version — Drugtopics

    # Medicaid Coverage of Obesity GLP-1s May Shift From Diabetes Version Published: 2026-09-30T14:00:00+00:00 Source: drugtopics.com (drugtopics.com) Language: en ## Story --- ## title: "Medicaid Coverage of Obesity GLP-1s May Shift From Diabetes Version" description: "Medicaid coverage of obesity-labeled GLP-1 receptor agonists may substitute for, rather than simply add to, diabetes-labeled…

  4. Lilly's oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its largest and longest type 2 diabetes study — EurekAlert!

    Lilly's oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its largest and longest type 2 diabetes study # Lilly's oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its largest and longest type 2 diabetes study By PR Newswire | September 30, 2026,…

  5. Newsom signs law allowing California-made GLP-1 drugs — Redding

    Newsom signs law allowing California-made GLP-1 drugs # California’s GLP-1 law could expand access to obesity treatment Ernesto Centeno Araujo USA TODAY NETWORK Sept. 29, 2026, 4:42 p.m. PT Gov. Gavin Newsom recently signed a law that would allow California to make and distribute a generic version of a popular class of weight-loss drugs through the state's CalRx program. California…

Daily TopFive for GLP-1 Daily. Links above go to the original articles. Follow and rate GLP-1 Daily on Apple Podcasts. Feedback? Email [email protected].

Todos os episódios de GLP-1 Daily: Ozempic & Wegovy News

Configurações

Exibição

Idioma

Define quais estações você vê primeiro na página inicial.

Histórico

As rádios e episódios ouvidos recentemente e suas últimas buscas ficam só neste navegador.

Avisos

Um aviso rápido quando um podcast que você segue tem um episódio novo. Desative podcasts individuais pelo sino na página deles.

Conta

Salve favoritos – no app e no site.

Atalhos de teclado

/
Abrir busca
Espaço
Reproduzir ou pausar
← →
No player: voltar 15 s, avançar 30 s (episódios) · na fileira: próximo bloco
↑ ↓
Na fileira: alvo dentro do bloco
Home / End
Na fileira: primeiro ou último bloco
Esc
Fechar janela ou menu
?
Esta visão geral
Tocando agora

Ir para a estação

A seguir

    Adicione episódios com “A seguir” – eles tocam depois do episódio atual.